Rani Therapeutics (RANI) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free RANI Stock Alerts $6.68 +0.12 (+1.83%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)markets.businessinsider.com - April 23 at 5:07 PMAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)markets.businessinsider.com - April 23 at 12:07 PMRani Therapeutics (NASDAQ:RANI) Trading 14.3% Higher americanbankingnews.com - April 18 at 1:52 AMRANI Rani Therapeutics Holdings, Inc.seekingalpha.com - April 14 at 10:51 PMAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)markets.businessinsider.com - April 2 at 9:37 AMCanaccord Genuity Group Trims Rani Therapeutics (NASDAQ:RANI) Target Price to $9.00marketbeat.com - March 27 at 8:28 AMRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 27 at 8:27 AMBuy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market Potentialmarkets.businessinsider.com - March 25 at 1:17 PMRani Therapeutics (NASDAQ:RANI) PT Lowered to $12.00 at HC Wainwrightmarketbeat.com - March 25 at 8:21 AMRani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 22 at 10:36 PMRANI: 2023 Resultsmsn.com - March 21 at 4:08 PMQ4 2023 Rani Therapeutics Holdings Inc Earnings Callfinance.yahoo.com - March 21 at 10:34 AMRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 21 at 10:34 AMRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023investorplace.com - March 20 at 10:02 PMRecap: Rani Therapeutics Hldgs Q4 Earningsbenzinga.com - March 20 at 7:33 PMRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Updateglobenewswire.com - March 20 at 4:05 PMEarnings Outlook For Rani Therapeutics Hldgsbenzinga.com - March 19 at 3:39 PMAnalysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)markets.businessinsider.com - March 16 at 8:57 PMRANI Apr 2024 2.500 putfinance.yahoo.com - March 16 at 5:06 AMRANI Apr 2024 5.000 putfinance.yahoo.com - March 15 at 10:52 PMRani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 15 at 4:05 PMAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)markets.businessinsider.com - March 13 at 2:26 PMIndividual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the companyfinance.yahoo.com - March 12 at 7:51 AMRani Therapeutics (NASDAQ:RANI) Stock Price Down 1.3%marketbeat.com - March 2 at 2:52 AMAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)markets.businessinsider.com - February 22 at 1:21 PMRANI: INITIATION – Realizing Oral Administration of Biologicsfinance.yahoo.com - February 20 at 1:56 PMSilicon Valley businesswomen share thoughts on mentoringbizjournals.com - February 19 at 4:05 PMWedbush Analysts Lower Earnings Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)marketbeat.com - February 9 at 7:52 AMBuy Rating Affirmed for Rani Therapeutics Holdings on Strong Clinical and Strategic Prospectsmarkets.businessinsider.com - February 6 at 4:06 PMRani Therapeutics Reports Positive Phase 1 Trial Outcomesmsn.com - February 6 at 11:06 AMRani Therapeutics Shares Exciting Clinical Trial Resultsmsn.com - February 6 at 11:06 AMWedbush Reaffirms Outperform Rating for Rani Therapeutics (NASDAQ:RANI)marketbeat.com - February 6 at 9:35 AMBuy Rating Affirmed for Rani Therapeutics on Strong Clinical and Strategic Milestonesmarkets.businessinsider.com - February 6 at 6:05 AMRani Therapeutics Sees Positive Results From Trial for CT-P43marketwatch.com - February 5 at 12:34 PMRani Reports Positive Topline Results From Phase 1 Clinical Study Of RT-111markets.businessinsider.com - February 5 at 12:34 PMRani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)finance.yahoo.com - February 5 at 12:34 PMAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Apollo Medical Holdings (AMEH) and Arcus Biosciences (RCUS)markets.businessinsider.com - January 30 at 12:48 PMAnalysts Conflicted on These Healthcare Names: Outlook Therapeutics (OTLK) and Cytokinetics (CYTK)markets.businessinsider.com - December 20 at 8:11 PMRani Therapeutics Holdings Inc Class Amorningstar.com - December 14 at 2:12 PMRani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonistfinance.yahoo.com - December 14 at 9:11 AMPromising Clinical Trial Results and Durability Potential Underpin Buy Rating for Century Therapeutics’ CNTY-101markets.businessinsider.com - December 13 at 6:57 PMRani Therapeutics nearly doubles footprint with 5-year Fremont leasebizjournals.com - December 11 at 6:04 PMRani Therapeutics CEO discloses purchase of 10K sharesmsn.com - December 8 at 1:56 PMWhat Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stockfinance.yahoo.com - December 7 at 1:33 PMRani Therapeutics CEO Talat Imran purchases 5,000 sharesmsn.com - December 6 at 2:15 PMRani Therapeutics says CEO Imran buys 20K class A sharesmsn.com - December 1 at 7:36 PMPleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stockfinance.yahoo.com - November 24 at 7:52 AMJean-Luc Butel Buys Handful Of Shares In Rani Therapeutics Holdingsfinance.yahoo.com - November 24 at 7:52 AMEdward Nash Reaffirms Buy Rating for Rani Therapeutics Holdings Amidst Clinical Program Changes and Financial Adjustmentsmarkets.businessinsider.com - November 10 at 3:37 PMPromising Financial Performance and RaniPill Platform Potential Bolster Buy Rating for Rani Therapeutics Holdingsmarkets.businessinsider.com - November 9 at 10:35 PM Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. RANI Media Mentions By Week RANI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.270.32▲Average Medical News Sentiment RANI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼22▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: URGN News PGEN News MREO News VTYX News NATR News ATAI News NLTX News FBLG News EPIX News ESPR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
